ERBB2 and breast cancer: The majority of patients received anthracycline-taxane-based NAC (HR-low/HER2-negative BC: 94.3%; TNBC: 89.0%), and only a small percentage of patients were treated with platinum (HR-low/HER2-negative BC: 12.9%; TNBC: 17.9%).